Wells Fargo
CSTL icon

Wells Fargo’s Castle Biosciences CSTL Stock Holding History

Wells Fargo’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$705K Buy
29,543
+16,651
+129% +$371K ﹤0.01% 4361
2026
Q1 		$316K Sell
12,892
-21,320
-62% -$698K ﹤0.01% 4412
2025
Q4 		$1.33M Buy
34,212
+10,233
+43% +$330K ﹤0.01% 3746
2025
Q3 		$546K Buy
23,979
+3,679
+18% +$74.7K ﹤0.01% 4247
2025
Q2 		$415K Buy
20,300
+3,953
+24% +$73.2K ﹤0.01% 4277
2025
Q1 		$327K Buy
16,347
+972
+6% +$24.1K ﹤0.01% 4372
2024
Q4 		$410K Buy
15,375
+3,460
+29% +$105K ﹤0.01% 4326
2024
Q3 		$340K Buy
11,915
+408
+4% +$10.4K ﹤0.01% 4242
2024
Q2 		$251K Buy
11,507
+2,081
+22% +$46.4K ﹤0.01% 4360
2024
Q1 		$209K Buy
9,426
+1,479
+19% +$32.2K ﹤0.01% 4444
2023
Q4 		$171K Buy
7,947
+1,546
+24% +$27.2K ﹤0.01% 4562
2023
Q3 		$108K Sell
6,401
-5,011
-44% -$87.6K ﹤0.01% 4733
2023
Q2 		$157K Buy
11,412
+5,578
+96% +$113K ﹤0.01% 4733
2023
Q1 		$133K Sell
5,834
-18,247
-76% -$446K ﹤0.01% 4677
2022
Q4 		$567K Buy
24,081
+19,979
+487% +$463K ﹤0.01% 3567
2022
Q3 		$107K Buy
4,102
+838
+26% +$23.5K ﹤0.01% 4566
2022
Q2 		$71K Sell
3,264
-101,099
-97% -$2.35M ﹤0.01% 4845
2022
Q1 		$4.68M Sell
104,363
-3,359
-3% -$139K ﹤0.01% 2506
2021
Q4 		$4.62M Sell
107,722
-462,813
-81% -$24.2M ﹤0.01% 2653
2021
Q3 		$37.9M Buy
570,535
+62,997
+12% +$4.43M 0.01% 1228
2021
Q2 		$37.2M Sell
507,538
-6,353
-1% -$420K 0.01% 1254
2021
Q1 		$35.2M Sell
513,891
-77,215
-13% -$5.8M 0.01% 1252
2020
Q4 		$39.7M Sell
591,106
-12,425
-2% -$674K 0.01% 1116
2020
Q3 		$31.1M Buy
603,531
+46,058
+8% +$2.05M 0.01% 1134
2020
Q2 		$21M Buy
557,473
+296,960
+114% +$10.1M 0.01% 1345
2020
Q1 		$7.77M Buy
260,513
+254,404
+4,164% +$7.68M ﹤0.01% 1870
2019
Q4 		$210K Buy
6,109
+2,510
+70% +$61.4K ﹤0.01% 4923
2019
Q3 		$65K Buy
+3,599
New +$79.8K ﹤0.01% 5480

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's CSTL Position: Q2 2026 in Review

Wells Fargo increased its Castle Biosciences (CSTL) stake by 129% in Q2 2026, buying an estimated $371K and bringing the position to 29,543 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #4361.

Wells Fargo first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $39.7M in Q4 2020. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Wells Fargo held 29,543 shares of Castle Biosciences worth $705K as of Q2 2026.
  • Wells Fargo bought 16,651 Castle Biosciences shares in Q2 2026, an estimated $371K.
  • Castle Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4361 holding.
  • Wells Fargo first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Wells Fargo's Castle Biosciences position peaked at $39.7M in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.